• locally advanced NSCLC - maintenance (M)
• laNSCLC - M - all population 1
• laNSCLC - M - EGFR mutant

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• durvalumab based treatment
• durvalumab alone

• versus all
• vs non active control
• vs placebo

  All patients Age < 65y (younger) Age > 65y Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male PDL1 < 25% PDL1 >25% smoker (current or former) smoker (never) stage IIIa stage IIIb

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

locally advanced NSCLC - maintenance (M), durvalumab based treatment vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;